Erenumab in Mechanism-based Migraine Treatment
Open Access
- 4 October 2021
- journal article
- review article
- Published by Turk Noroloji Dernegi in Türk Nöroloi Dergisi
- Vol. 27 (3), 229-239
- https://doi.org/10.4274/tnd.2021.08784
Abstract
Migraine is a type of primary headache with recurrent attacks, negatively affects the daily living activities of sufferers because of its severity, and causes a heavy economic burden. The economic, social, and physical burdens of migraine grow with the increasing frequency of headache attacks. Mechanism-based treatments are increasingly needed, especially for those with chronic migraine (CM) or episodic migraine (EM) with frequent attacks. Conventional migraine-preventive medications have been essentially developed for some other diseases and shown to be also effective against migraine headaches. Efficacy, safety, and tolerability issues limit their use for an adequate duration, and most patients are under the risk of medication-overuse headache because of the ineffectiveness of attack treatments. In recent decades, a better understanding of migraine pathophysiology has given a new direction to migraine drug research to fulfill the unmet need for the development of migraine-specific medications. Calcitonin gene-related peptide (CGRP) has attracted attention with its potential role in migraine pathogenesis and has become the focus of drug research in this area as of the 1990s. The first monoclonal antibody developed and approved for the treatment of migraine is erenumab. Being the only therapeutic antibody against the CGRP receptor, erenumab differs from the other monoclonal antibodies for migraine prevention that target the CGRP ligand. Erenumab is a fully human, immunoglobulin G2 class monoclonal antibody with no immunomodulatory effect. It blocks the CGRP receptor with high affinity and selectivity and prevents binding of the CGRP ligand to this receptor. It does not have a significant effect on other receptors in the calcitonin receptor family. Erenumab has been shown to diminish the number of migraine days and the need for attack treatment and to improve patient-reported outcomes in patients with EM and CM.Keywords
This publication has 51 references indexed in Scilit:
- Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide ReceptorThe Journal of pharmacology and experimental therapeutics, 2015
- Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and PreventionHeadache: The Journal of Head and Face Pain, 2015
- Calcitonin Gene-Related Peptide (CGRP): A New Target for MigraineAnnual Review of Pharmacology and Toxicology, 2015
- IgG Subclasses and Allotypes: From Structure to Effector FunctionsFrontiers in Immunology, 2014
- Migrende Profilaktik TedaviNöro Psikiyatri Arşivi, 2013
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS‐II)Headache: The Journal of Head and Face Pain, 2013
- A systematic review of the psychosocial difficulties relevant to patients with migraineThe Journal of Headache and Pain, 2012
- Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)The Journal of Headache and Pain, 2012
- One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adultsThe Journal of Headache and Pain, 2012
- Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based StudyHeadache: The Journal of Head and Face Pain, 2008